



HEVOLUTION

Global
Healthspan
Summit 2025

Hevolution Fact Sheet

Hevolution is a global non-profit dedicated to advancing the emerging healthspan science field. We provide grants and early-stage company investments to incentivize independent research and entrepreneurship that drive transformative innovations to extend healthy years of life for people everywhere.

Our commitment is clear: we're focused on increasing the number of safe and effective treatments that reach the market, accelerating the drug development process, and making these therapies accessible for everyone. With an annual budget of up to \$1 billion, we are actively growing the number of researchers worldwide focused on aging, expanding the number of companies dedicated to tackling this challenge, and attracting substantial investment into aging research.

Our mission is to shift the global conversation from simply extending lifespan to enhancing healthspan. In two-short years since operationalizing in 2022, we've already allocated over \$400 million to ignite progress. As the largest philanthropic healthspan funder, we're poised to accelerate our vision to convene and catalyze this vital field.

Global Imperative

While life expectancy has increased, the quality of those added years often falls short. We are living longer, but we are spending more years living with the symptoms of aging such as cardiovascular disease, cancer, dementia, and frailty. By 2050, the global population over 60 years is set to double to 2 billion. What is more, two-thirds of people over 60 will live in low- and middle-income countries. Health and economic systems are ill-equipped to handle rapidly aging populations and are facing unprecedented financial pressure from rising costs and shrinking workforces.

Unwavering Commitment

Every human has the right to live a healthier life, whatever their circumstances. Hevolution is dedicated to making aging healthier for everyone. With a budget of up to \$1 billion per year, Hevolution is investing in cutting-edge science to understand and address the root causes of aging.

Hevolution aims to:

- ⌋ Increase the number of safe and effective treatments entering the market
- ⌋ Compress the timeline of drug development, using the latest tools and technologies
- ⌋ Increase accessibility to therapeutics that extend healthy lifespan for the benefit of all humanity

Hevolution aims to achieve this by:

- ⌋ Increasing the number of researchers in geroscience/healthspan science globally
- ⌋ Expanding the number of companies working in the field
- ⌋ Attracting funding to the aging field.

Dedication To Science

Aging results from the accumulation of molecular and cellular damage, leading to a growing risk of disease over time. In fact, aging is the number one risk factor for most chronic diseases. Hevolution supports innovation in life sciences and medicine that focuses on aging biology, rather than the individual diseases it causes. Embracing the power of collaboration and partnership, Hevolution supports innovative, peer-reviewed science for a wide range of scientific areas related to understanding the complex biological processes behind aging.

Strategic Investments

Aging science is a promising, essential part of healthcare investment with high untapped potential to extend healthy human life in the 21st century. As an impact-driven venture capital fund, Hevolution helps make emerging healthspan technologies more accessible and less risky for the market. Hevolution is redefining aging science as a viable investment by delivering needed capital, mitigating the technical, clinical, regulatory, and investment risks inherent in the health sector, and incentivizing a greater focus on prevention. As a global non-profit, Hevolution can take more significant risks to give promising therapies that could improve aging on a worldwide scale a chance.

Track Record For Impact

Hevolution is making an impact in three crucial ways:

1. Collaborating:

Hevolution is uniting diverse perspectives and collaborating with top institutions such as the U.S. National Academy of Medicine, the Buck Institute, the American Federation for Aging Research (AFAR), and multiple universities worldwide. Through initiatives like our recent report, Enabling a Healthy Lifespan for Saudi Arabia and the Global Healthspan Report and Survey, Hevolution is identifying gaps, sharing valuable insights, and offering practical recommendations to guide collaborative efforts to build collective understanding of healthspan and to make aging healthier for all.

2. Convening:

Hevolution supports a wide variety of scientific meetings, conferences, and workshops to bring experts together and advance the healthspan field. Hevolution's inaugural Global Healthspan Summit is convening global experts on an unparalleled scale to mobilize action to address unhealthy aging.

3. Catalyzing

Hevolution has committed over \$400 million (SAR 1.5 billion) through grants (~170 projects and ~200 grantees worldwide) and investments to accelerate the science and medicine behind aging.

Science Grants

Kingdom of Saudi Arabia

HF-KSA: \$3.1 million is a two-year grant program to create the first cohort of aging researchers in Saudi Arabia, funding 11 grantees from King Faisal Specialist Hospital & Research Center, King Abdullah International Medical Research Center, King Abdullah University of Science and Technology, and other prestigious institutions to explore areas such as the microbiome, aging biomarkers, and senescence.

HF-SAP (2024 Hevolution Foundation Saudi Arabia Postdoctoral Fellowship): \$1.9 million) program aims to develop and introduce new Saudi scientists to the field of aging research by facilitating their development as creative and innovative future scholars in the field.

International

HF-NI (New Investigator Awards): \$20.2 million to expand and support early-career researchers through the American Federation for Aging Research (AFAR).

HF-GRO (Hevolution Foundation Geroscience Research Opportunities Program): \$230 million to fund pre-clinical projects in aging biology and translational geroscience on an international scale.

HF-PTG (Hevolution Foundation Postdoctoral Training in Geroscience): Over \$5 million to identify accomplished PhD/MD/PhD candidates specializing in the aging biology and/or geroscience.

International

HF-GLA (Hevolution Foundation Geroscience in Latin America): \$5 Million in an international effort to expand, accelerate progress, and foster talent in biology of aging and geroscience research in Latin America. The major goal is to identify and support promising research that will contribute long-term towards improving healthy lifespan for the betterment of all of humanity.

HF-AGE Hevolution Foundation Advancing Geroscience Efforts: Over \$27 million for the program to fund research deemed meritorious by the U.S. National Institute on Aging that failed to secure funds; supporting nine innovative projects in areas such as mitochondrial dysfunction, spatial transcriptomics, and epigenetics.

International Partnerships

Albert Einstein College of Medicine: \$20 million grant for research focused on senescence and aging, led by Dr. Ana Maria Cuervo of the National Academy of Sciences.

Buck Institute: \$21 million for a novel multi-year partnership to accelerate discoveries toward therapeutic interventions specifically targeting aging.

Impetus Grants: \$7 million in matching funds to date supporting 14 innovative academic healthspan science research projects, from causality of methylation clocks to in-situ genome-scale measurements of aging mechanisms.

Indiana University School of Public Health-Bloomington: \$2 million for an endowed chair to advance the study of healthy aging on a global scale.

Northwestern University: \$32.4 million partnership to support research focused on defining a healthy proteostasis and maintaining proteostasis in a robust, resilient state.

Hevolution, XPRIZE Healthspan partnership: \$40 million as the leading and largest single funder to fund a 7-year global competition that requires teams to test and verify therapeutics that can restore a decade of muscle, immune, and cognitive functioning of people aged 65 to 80 in one year or less.

Impact Investments Highlights

Aeovian Pharmaceuticals:

\$20 million investment to fund the Company's entry into the clinic with its selective mTOR1 inhibitor. mTOR is one of the most "validated" targets for potentially improving healthy aging, & the availability of a safer, selective agent, could open up healthspan indications for this drug class.

Rubedo Life:

\$2 million investment targeting cellular senescence, one of the hallmarks of aging. The company's machine learning-enabled platform may enable it to identify and characterize different types of senescent cells - currently a major bottleneck in the aging field.

Vandria SA:

\$7.9 million completing a series A financing round with investors Dolby Family Ventures and ND Capital, part of a total \$30.7 million investment. This will fund the Company's entry into the clinic with their proprietary mitophagy inducers. Impaired mitophagy is one of the classic "hallmarks of aging," and the Company has molecules that may improve cognitive ability in older patients as well as a molecule that could improve muscle function in the elderly via this pathway.

Breakthrough Innovation Alliance:

\$10 million in funding to bring leading entrepreneurs, investors, and industry partners together to provide mentorship/capital to high-potential companies working on breakthroughs in healthspan.